Phototrexate is a photochromic antifolate drug developed at the Institute for Bioengineering of Catalonia (IBEC, The Barcelona Institute of Science and Technology).

In particular, it is a photopharmacological agent[1][2] that behaves as light-regulated inhibitor of the dihydrofolate reductase (DHFR) enzyme.

[3][4] Phototrexate is a photoisomerizable structural analogue of the chemotherapy agent methotrexate.

[5] Pharmacological effects of phototrexate can be switched on and off by UVA and visible light, respectively.

This antineoplastic or immunomodulatory drug article is a stub.